Manojkumar Bupathi, MD, MS, from Rocky Mountain Cancer Centers, conducted a safety analysis on cohort 1 of the TROPHY-U-01 phase 2 study.
The study evaluated the use of sacituzumab govitecan (SG) in patients with metastatic urothelial cancer (mUC) who had experienced disease progression after receiving platinum-based chemotherapy and a checkpoint inhibitor (CPI).
The safety analysis specifically focused on the UGT1A1 status of the patients.
The study included a total of 113 patients who were administered SG as a treatment for mUC. UGT1A1 is a gene responsible for the metabolism of irinotecan, a component of SG.
Variations in the UGT1A1 gene can affect how the body processes irinotecan, potentially leading to increased toxicity.
Therefore, it was crucial to assess the safety profile of SG based on the UGT1A1 status of the patients.
The safety analysis revealed that the incidence of adverse events (AEs) was generally consistent across different UGT1A1 status groups.
The most common AEs reported in the study were fatigue, diarrhea, nausea, decreased appetite, and neutropenia.
Importantly, there were no new or unexpected safety concerns identified in any of the UGT1A1 status groups.
The analysis also compared the incidence and severity of neutropenia, a known side effect of SG, among the UGT1A1 status groups.
Neutropenia refers to a decrease in neutrophil count, which can increase the risk of infection.
The results showed that the incidence and severity of neutropenia were similar across the different UGT1A1 status groups, suggesting that UGT1A1 status did not impact the occurrence or severity of this particular side effect.
Based on the safety analysis, it can be concluded that SG demonstrated an acceptable safety profile in patients with mUC who had progressed after receiving platinum-based chemotherapy and a CPI, regardless of their UGT1A1 status.
These findings are significant as they provide valuable insights into the safe administration of SG in this patient population.
Dr. Bupathi’s study contributes to the growing body of evidence on the use of SG in the treatment of mUC.
Sacituzumab govitecan has shown promising efficacy in this patient population, with previous studies demonstrating a favorable overall response rate and progression-free survival.
The safety analysis by UGT1A1 status adds an additional layer of understanding regarding the tolerability of SG, further supporting its potential as a treatment option for patients with mUC.
In conclusion, Dr. Manojkumar Bupathi’s safety analysis of the TROPHY-U-01 cohort 1 study demonstrates that sacituzumab govitecan has an acceptable safety profile in patients with metastatic urothelial cancer who have progressed after platinum-based chemotherapy and a checkpoint inhibitor.
The UGT1A1 status did not significantly impact the occurrence or severity of adverse events, including neutropenia.
These findings contribute to the ongoing research on the use of SG in this patient population and provide valuable insights for clinical practice.